-
Protein Chemistry Biotech Gains Collaboration, Venture Funds
An enterprise discovering new drugs with optical light-based protein chemistry is emerging from stealth, including work with biopharmaceutical company Genentech.
-
Trial Shows Anti-Inflammatory Drug Stops Covid-19 Hospitalization
Findings from a clinical trial show an anti-inflammatory drug reduces new symptoms among people with Covid-19 infections and keeps them out of the hospital.
-
Infographic – Biotech Index Struggles to Regain Ground
NBI is showing signs of life, rising somewhat from its low point for the year and since the end of the third quarter, but still down almost 12 percent since the start of the year.
-
Company Started for Gene Editing Rare Inherited Diseases
A new enterprise is formed to develop gene-editing therapies for mitochondrial disorders, rare inherited mutations in the energy centers of cells.
-
Implanted Organoid Connects to Brain, Reacts to Visual Cues
Engineers and neuroscientists developed a circuit that in lab mice connects implanted lab-grown brain tissue to the brain’s cognitive center and responds to visual stimuli.
-
Over-the-Counter Naloxone Receiving Faster FDA Review
The opioid overdose drug naloxone in nasal spray form is receiving priority review from the Food and Drug Administration as an over-the-counter drug.
-
Peptide Discovery Company to Gain $3.3B in Licensing Deals
A discoverer of therapeutic peptides signed licensing deals in the past few days with two drug makers that could bring the company as much as $3.3 billion.
-
Infographic – Cancer Start-Up Venture Funds Decline
Funding for new enterprises creating products and services that treat or detect cancer fell more than 40 percent from last year.
-
Food Protein Biotech Adds €4M in Seed Funds
A new company creating protein ingredients for food products from carbon dioxide converted by engineered bacteria is raising €4 million more in seed funds.
-
Cell Biology Tools Companies Merge in $57.8M Deal
Two providers of technologies for cellular analysis are merging to form a new company focusing on cell biology research tools, in a sign of continued industry consolidation.